<DOC>
	<DOCNO>NCT01702181</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics safety OPA-15406 adult subject atopic dermatitis</brief_summary>
	<brief_title>A Safety Study Evaluate Use Effectiveness Topical Ointment Treat Adults With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adult subject 1865 year age Diagnosis atopic dermatitis ( AD ) AD affect least 5 % total Body Surface Area ( BSA ) Part 1 least 10 % BSA Part 2 , include face , neck , head Have positive inadequate response one treatment course standard AD therapy include topical steroid , UV light A , narrowband UV B , UV light B . Use systemic topical therapy contact atopic dermatitis within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Atopic Dermatitis , Eczema</keyword>
</DOC>